Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions

Saroj Purohit, Ofelia A Alvarez, Robert O'Brien, Samita Andreansky

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Defects in the immune system may affect vaccine responsiveness. Because of the splenic hypofunction and abnormal opsonic activity, it was unknown whether patients with sickle cell disease (SCD) would respond appropriately to H1N1 vaccination. The objective of this study was to assess seroprotective post-vaccine H1N1 antibody response in children with SCD. Procedure: Serum antibody titers were measured by hemagglutination inhibition and microneutralization (MN) assays. Correlations were established between clinical and treatment parameters and immune response. Results: Twenty-nine of 38 (76.3%) subjects (mean age 11±5.4 years) had durable protective antibody titers 8±1.6 months (range 5-12 months) post-vaccination. Lessened immune response was not associated with time interval from vaccination, splenectomy, or hydroxyurea treatment. Lack of antibody response was associated with age less than 3 years and treatment with chronic transfusions. Of the nine non-responders, seven were on chronic transfusions (39% unresponsiveness rate in the transfused group). The difference in the number of patients with seropositivity between the non-transfused and the transfused groups was statistically significant (P=0.039). Conclusions: Most subjects were able to mount an influenza-specific antibody response against the inactivated H1N1 vaccine. Similar to the general population, children less than 3 years were less likely to respond. In addition, patients on chronic transfusions were less likely to respond when compared to non-transfused children. Clinicians should be aware of the possibility of decreased vaccine response in patients with SCD on chronic transfusions. We postulate that transfusion-related immunomodulation (TRIM) may be related to decreased response.

Original languageEnglish
Pages (from-to)1280-1283
Number of pages4
JournalPediatric Blood and Cancer
Volume59
Issue number7
DOIs
StatePublished - Dec 15 2012

Fingerprint

Inactivated Vaccines
Sickle Cell Anemia
Antibody Formation
Vaccination
Vaccines
Hydroxyurea
Immunomodulation
Antibodies
Hemagglutination
Splenectomy
Human Influenza
Immune System
Therapeutics
Serum
Population

Keywords

  • H1N1
  • Immunity
  • Influenza A
  • Sickle cell anemia
  • Transfusion

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions. / Purohit, Saroj; Alvarez, Ofelia A; O'Brien, Robert; Andreansky, Samita.

In: Pediatric Blood and Cancer, Vol. 59, No. 7, 15.12.2012, p. 1280-1283.

Research output: Contribution to journalArticle

@article{aba9e16c71034892b7eee1a03d48b8d6,
title = "Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions",
abstract = "Background: Defects in the immune system may affect vaccine responsiveness. Because of the splenic hypofunction and abnormal opsonic activity, it was unknown whether patients with sickle cell disease (SCD) would respond appropriately to H1N1 vaccination. The objective of this study was to assess seroprotective post-vaccine H1N1 antibody response in children with SCD. Procedure: Serum antibody titers were measured by hemagglutination inhibition and microneutralization (MN) assays. Correlations were established between clinical and treatment parameters and immune response. Results: Twenty-nine of 38 (76.3{\%}) subjects (mean age 11±5.4 years) had durable protective antibody titers 8±1.6 months (range 5-12 months) post-vaccination. Lessened immune response was not associated with time interval from vaccination, splenectomy, or hydroxyurea treatment. Lack of antibody response was associated with age less than 3 years and treatment with chronic transfusions. Of the nine non-responders, seven were on chronic transfusions (39{\%} unresponsiveness rate in the transfused group). The difference in the number of patients with seropositivity between the non-transfused and the transfused groups was statistically significant (P=0.039). Conclusions: Most subjects were able to mount an influenza-specific antibody response against the inactivated H1N1 vaccine. Similar to the general population, children less than 3 years were less likely to respond. In addition, patients on chronic transfusions were less likely to respond when compared to non-transfused children. Clinicians should be aware of the possibility of decreased vaccine response in patients with SCD on chronic transfusions. We postulate that transfusion-related immunomodulation (TRIM) may be related to decreased response.",
keywords = "H1N1, Immunity, Influenza A, Sickle cell anemia, Transfusion",
author = "Saroj Purohit and Alvarez, {Ofelia A} and Robert O'Brien and Samita Andreansky",
year = "2012",
month = "12",
day = "15",
doi = "10.1002/pbc.24206",
language = "English",
volume = "59",
pages = "1280--1283",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions

AU - Purohit, Saroj

AU - Alvarez, Ofelia A

AU - O'Brien, Robert

AU - Andreansky, Samita

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Background: Defects in the immune system may affect vaccine responsiveness. Because of the splenic hypofunction and abnormal opsonic activity, it was unknown whether patients with sickle cell disease (SCD) would respond appropriately to H1N1 vaccination. The objective of this study was to assess seroprotective post-vaccine H1N1 antibody response in children with SCD. Procedure: Serum antibody titers were measured by hemagglutination inhibition and microneutralization (MN) assays. Correlations were established between clinical and treatment parameters and immune response. Results: Twenty-nine of 38 (76.3%) subjects (mean age 11±5.4 years) had durable protective antibody titers 8±1.6 months (range 5-12 months) post-vaccination. Lessened immune response was not associated with time interval from vaccination, splenectomy, or hydroxyurea treatment. Lack of antibody response was associated with age less than 3 years and treatment with chronic transfusions. Of the nine non-responders, seven were on chronic transfusions (39% unresponsiveness rate in the transfused group). The difference in the number of patients with seropositivity between the non-transfused and the transfused groups was statistically significant (P=0.039). Conclusions: Most subjects were able to mount an influenza-specific antibody response against the inactivated H1N1 vaccine. Similar to the general population, children less than 3 years were less likely to respond. In addition, patients on chronic transfusions were less likely to respond when compared to non-transfused children. Clinicians should be aware of the possibility of decreased vaccine response in patients with SCD on chronic transfusions. We postulate that transfusion-related immunomodulation (TRIM) may be related to decreased response.

AB - Background: Defects in the immune system may affect vaccine responsiveness. Because of the splenic hypofunction and abnormal opsonic activity, it was unknown whether patients with sickle cell disease (SCD) would respond appropriately to H1N1 vaccination. The objective of this study was to assess seroprotective post-vaccine H1N1 antibody response in children with SCD. Procedure: Serum antibody titers were measured by hemagglutination inhibition and microneutralization (MN) assays. Correlations were established between clinical and treatment parameters and immune response. Results: Twenty-nine of 38 (76.3%) subjects (mean age 11±5.4 years) had durable protective antibody titers 8±1.6 months (range 5-12 months) post-vaccination. Lessened immune response was not associated with time interval from vaccination, splenectomy, or hydroxyurea treatment. Lack of antibody response was associated with age less than 3 years and treatment with chronic transfusions. Of the nine non-responders, seven were on chronic transfusions (39% unresponsiveness rate in the transfused group). The difference in the number of patients with seropositivity between the non-transfused and the transfused groups was statistically significant (P=0.039). Conclusions: Most subjects were able to mount an influenza-specific antibody response against the inactivated H1N1 vaccine. Similar to the general population, children less than 3 years were less likely to respond. In addition, patients on chronic transfusions were less likely to respond when compared to non-transfused children. Clinicians should be aware of the possibility of decreased vaccine response in patients with SCD on chronic transfusions. We postulate that transfusion-related immunomodulation (TRIM) may be related to decreased response.

KW - H1N1

KW - Immunity

KW - Influenza A

KW - Sickle cell anemia

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=84867355516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867355516&partnerID=8YFLogxK

U2 - 10.1002/pbc.24206

DO - 10.1002/pbc.24206

M3 - Article

C2 - 22628221

AN - SCOPUS:84867355516

VL - 59

SP - 1280

EP - 1283

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -